Orai1 and STIM1 are critical components of Ca 2+ release-activated Ca 2+ (CRAC) channels that mediate store-operated Ca 2+ entry (SOCE) in immune cells. Although it is known that Orai1 and STIM1 co-cluster and physically interact to mediate SOCE, the cytoplasmic machinery modulating these functions remains poorly understood. We sought to find modulators of Orai1 and STIM1 using affinity protein purification and identified a novel EF-hand protein, CRACR2A (also called CRAC regulator 2A, EFCAB4B or FLJ33805). We show that CRACR2A interacts directly with Orai1 and STIM1, forming a ternary complex that dissociates at elevated Ca 2+ concentrations. Studies using knockdown mediated by small interfering RNA (siRNA) and mutagenesis show that CRACR2A is important for clustering of Orai1 and STIM1 upon store depletion. Expression of an EF-hand mutant of CRACR2A enhanced STIM1 clustering, elevated cytoplasmic Ca 2+ and induced cell death, suggesting its active interaction with CRAC channels. These observations implicate CRACR2A, a novel Ca 2+ binding protein that is highly expressed in T cells and conserved in vertebrates, as a key regulator of CRAC channel-mediated SOCE.
. Recent studies have identified STIM1, a Ca 2+ -binding protein localized in the endoplasmic reticulum (ER), as an important component of SOCE 6, 7 . STIM1 contains a single transmembrane (TM) segment; it detects ER Ca 2+ through its amino terminus and has a long carboxy-terminal cytoplasmic region. Upon ER Ca 2+ depletion, STIM1 oligomerizes and translocates to plasma membrane (PM)-proximal regions to activate SOCE 6, 8, 9 . Subsequent studies have identified Orai1 as a pore subunit of the CRAC channels [10] [11] [12] [13] [14] [15] [16] . Upon store depletion, Orai1 also clusters on the PM close to STIM1 clusters 17, 18 . Amplified CRAC currents have been observed upon coexpression of Orai1 and STIM1, suggesting that these are the limiting and essential components of CRAC channels 15, [19] [20] [21] . Several studies have shown that the cytoplasmic fragment of STIM1 interacts directly with Orai1 and is sufficient to activate CRAC currents when co-expressed with Orai1 [22] [23] [24] [25] [26] [27] [28] . However, the cellular machinery modulating Orai1-STIM1 interactions remains unexplored.
Recent studies, in which a chemically inducible bridge was formed with linkers of variable lengths between the PM and ER membranes, showed that Orai1 exists in a macromolecular complex with a 11-14 nm protrusion into the cytoplasm 29 . These results indicate the presence of additional components within the Orai1-STIM1 complex 29 . Using immunoaffinity purification of Orai1 after store depletion, we identified a macromolecular complex containing Orai1, STIM1 and putative interactors. An EF-hand-containing protein, CRACR2A, was validated as an important regulator of Orai1-STIM1 interaction. Our results show that CRACR2A interacts directly with the cytoplasmic regions of Orai1 and STIM1, forming a ternary complex. CRACR2A dissociates from Orai1 and STIM1 at higher Ca 2+ concentrations ([Ca   2+   ] ). An EF-hand mutant of CRACR2A enhanced STIM1 clustering and elevated cytoplasmic [Ca 2+ ], thereby causing cell death in T cells. These observations suggest a role of CRACR2A as a cytoplasmic Ca 2+ sensor that modulates multiple steps of CRAC channel activation, including translocation and clustering of Orai1 and STIM1 by direct protein interaction.
RESULTS

Orai1 and STIM1 exist in a macromolecular protein complex
To identify novel regulators of the CRAC channel using Orai1 for affinity purification, we generated HeLa cells stably expressing Orai1 and STIM1 (HeLa O+S cells). Presence of an active CRAC channel complex was verified by detection of amplified CRAC currents ( (Fig. 1b) . Under resting conditions, STIM1 was primarily detected in a ~200 kDa protein complex (Fig. 1b, right) , possibly as a dimer, whereas it co-migrated with Orai1 upon store depletion. These results are consistent with the observation that STIM1 self-associates at rest and forms a high MW protein complex upon stimulation 9, 30, 31 .
Identification of CRACR2A as a binding partner of Orai1 and STIM1
To identify the binding partners of Orai1, fractions containing Orai1 were pooled, immunoprecipitated with resin coated with anti-FLAG antibody and eluted with the FLAG peptide. Samples from HeLa cells showed very few non-specific bands, whereas those from HeLa O+S cells showed some specific bands (Fig. 1c) . Enrichment of different size bands in resting or store-depleted conditions suggested the presence of discrete binding partners of Orai1 (Fig. 1c, asterisks) . Specific bands after store depletion were excised and analysed by mass spectrometry. Detection of STIM1 peptides served as a positive control (>17 peptides). . Left two panels, HeLa cells stably expressing either STIM1 (HeLa) or STIM1 and Orai1 (Orai1) were transfected with a plasmid encoding CRACR2A. After immunoprecipitation with anti-FLAG resin (Orai1) and elution with the FLAG peptide, eluted fractions were immunoblotted using anti-STIM1, anti-CRACR2A and anti-FLAG (Orai1) antibodies. Right two panels, HeLa cells stably expressing STIM1 were transfected with plasmids encoding Myc-Orai1 alone (Vec) or together with FLAG-CRACR2A (CRACR2A). After immunoprecipitation with anti-FLAG resin (CRACR2A), precipitates were immunoblotted with anti-STIM1, anti-Myc (Orai1) and anti-FLAG (CRACR2A) antibodies. (b) CRACR2A directly binds to the N terminus of Orai1. Left panels, GST pulldown analysis was performed between full-length GST-Orai1 and 6X His-tagged CRACR2A or CRACR2A EF2MUT proteins in the presence or absence of 2 mM CaCl 2 . Lower panel, input levels of GST-Orai1. Right panels, pulldown analysis with GST-fused fragments of the N terminus (N, amino acids 64-91), intracellular loop (intra, amino acids 137-173) and the C terminus (C, amino acids 254-301) of Orai1 and full-length 6X
His-tagged CRACR2A. Lower panel shows input levels of Orai1 fragments. All the recombinant proteins were purified from E. coli. (c) CRACR2A interacts with Orai2 and Orai3 proteins. HeLa cells stably expressing STIM1 were transfected with plasmids encoding FLAG-Orai2 (FO2, top) or FLAG-Orai3 (FO3, bottom) together with Myc-CRACR2A. Lysates were immunoprecipitated with anti-FLAG resin and immunoblotted for detection of CRACR2A (anti-Myc, left, asterisks) and Orai2 or Orai3 (anti-FLAG, right). NS, non-specific band. (d) Interaction between the cytoplasmic fragments of STIM1 and CRACR2A. Top, schematic of STIM1 with cytoplasmic domains of coiled-coil (CC, amino-acid residues 250-400), serine/threonine-rich sequence (S/T, residues 400-600) and PEST sequence (residues 600-685). The CAD/SOAR fragment is indicated. Purified GST-fused STIM1 fragments were immunoblotted with anti-GST antibodies (left). Their interactions with purified full-length Orai1, CRACR2A or STIM1 proteins were assessed by pulldown analysis in the absence (-Ca   2+ ) or presence (+Ca 2+ ) of 2 mM CaCl 2 . STIM1 fragments and CRACR2A were purified from E. coli, and full-length Orai1 and STIM1 proteins were purified from baculovirusinfected insect cells. For full scans see Supplementary Information, Fig. S12 .
In addition to STIM1, p45, renamed as CRACR2A (also called CRAC regulator 2A, EFCAB4B, FLJ33805 or FLJ33046; amino acid sequence of the transcript NM_032680), was identified as a binding partner of Orai1. The N terminus of CRACR2A contains two predicted EF hands and its C terminus has a predicted coiled-coil domain and a leucine-rich motif that is highly conserved among vertebrates ( Fig. 1d ; Supplementary  Information, Fig. S2 ). Fluorescence protease protection assays 32, 33 showed a predominantly cytoplasmic localization of CRACR2A ( Supplementary  Information, Fig. S3 ).
To examine whether CRACR2A binds Orai1, we carried out immunoprecipitation and pulldown analysis. For immunoprecipitation experiments, HeLa cells stably expressing either STIM1 alone or STIM1 and Orai1 proteins were transiently transfected with a plasmid encoding CRACR2A. As seen in Fig. 2a, STIM1 and CRACR2A both co-immunoprecipitated with Orai1 and showed enhanced binding upon store depletion. These results were further validated by reverse immunoprecipitation using FLAGtagged CRACR2A (Fig. 2a, right) . To test for a direct interaction between CRACR2A and Orai1, recombinant proteins purified from Escherichia coli ( Supplementary Information, Fig. S4 ) were used for in vitro binding assays. Glutathione S-transferase (GST) pulldown analysis showed a strong interaction between CRACR2A and Orai1 in the absence of Ca 2+ , whereas the binding was minimal in the presence of 2 mM Ca 2+ (Fig. 2b , left). To confirm an inhibitory role of Ca
2+
, we used an EF-hand mutant of CRACR2A that abolishes Ca 2+ binding (CRACR2A
EF2MUT
, Fig. 1d and see below). As shown in Fig. 2b , Ca 2+ had no effect on the Orai1-CRACR2A EF2MUT interaction, supporting its inhibitory role.
For domain interaction studies, we purified GST-fused fragments of the N and C termini and the intracellular loop of Orai1 ( Fig. 2b, right ; Supplementary Information, Fig. S4d ). The N-terminal fragment of Orai1 consisted of the amino acids 64-93, because truncation of first 63 residues did not alter CRACR2A binding (data not shown). These interaction studies showed that CRACR2A binds to the N terminus of Orai1 in a Ca 2+ -sensitive manner, with elevated Ca 2+ favouring its dissociation from Orai1 (Fig. 2b, right) . Given that amino acids 64-93 of Orai1 are highly conserved among the Orai family, we examined interaction of CRACR2A with Orai2 and Orai3. CRACR2A co-immunoprecipitated with Orai2 and Orai3 suggesting a conserved binding mechanism with all the Orai proteins (Fig. 2c) . Because CRACR2A co-immunoprecipitated with Orai1 and STIM1, we hypothesized that Orai1, STIM1 and CRACR2A may form a ternary complex though direct interaction. To examine a direct interaction of STIM1 with CRACR2A, three different GST fusion proteins of the cytoplasmic domain of STIM1, corresponding to coiled-coil domain (CC), serine/threonine (S/T)-rich sequence, and proline/lysine-rich sequence (PEST), were examined (Fig. 2d) . Full-length CRACR2A bound to the CC and PEST domains of STIM1 and the interaction was reduced in the presence of Ca
2+
. On the other hand, the S/T rich sequence, which did not bind to CRACR2A, was identified as a STIM1 multimerization and Orai1 interaction domain (Fig. 2d) . This sequence partially overlaps with the recently identified CAD/SOAR domains (amino acids 342-448) of STIM1, which directly interact with Orai1 [22] [23] [24] . Together, these data suggest that CRACR2A binds to both Orai1 and STIM1 in a Ca 2+ -sensitive manner.
Identification of a CRACR2A family member, CRACR2B
BLAST and Homologene analysis revealed a homologue of CRACR2A, renamed as CRACR2B (also called EFCAB4A, FLJ46033). NCBI (Genbank) depicts one transcript encoded by the human CRACR2B gene (NM_173584), whereas Ensembl shows four transcripts (ENST00000321883, 327417, 450448 and 450828) with different intronexon architecture. To characterize the mRNA sequence of human CRACR2B, we cloned its full-length complementary DNA from Jurkat T cells (registered as GenBank accession number GU952799). Our sequencing analysis revealed similar intron-exon architecture between human and mouse CRACR2B ( Supplementary Information, Fig. S5 ). Sequence alignment of human CRACR2A and CRACR2B proteins showed an overall identity of 36% (pairwise BLAST analysis) with a conserved primary structure of predicted EF-hand motifs and a coiledcoil domain.
CRACR2 proteins have an important role in SOCE
To examine the physiological role of CRACR2 proteins, we measured SOCE in Jurkat T cells upon siRNA-mediated depletion of CRACR2A or CRACR2B. As seen in Fig. 3a , depletion of CRACR2A decreased SOCE by 50%, whereas that of CRACR2B had a mild effect. Consistent with a decrease in SOCE, depletion of CRACR2A resulted in a stronger impairment in interleukin (IL)-2 production by Jurkat T cells than that of CRACR2B (Fig. 3b) . Surprisingly, in HEK293 cells, depletion of CRACR2B had a stronger effect on SOCE than that of CRACR2A (Fig. 3a, bottom) . Specificity and efficiency of CRACR2 knockdown was examined by PCR with reverse transcription (RT-PCR) and immunoblotting ( Supplementary  Information, Fig. S6a-d) . To determine the reason for the differences between Jurkat and HEK293 cells, we measured the expression levels of CRACR2 transcripts in various human tissues and cell lines. Quantitative RT-PCR analysis revealed abundant expression of CRACR2A transcripts in spleen and thymus distinct from CRACR2B (Fig. 3c) . Among cell lines, CRACR2A transcripts were higher in Jurkat T cells than in HEK293 or HeLa cells, whereas those of CRACR2B were higher in HEK293 cells (Fig. 3c) . Because CRACR2A transcripts were abundant in Jurkat T cells, we examined their expression in primary T cells. Murine thymocytes and naïve and effector CD4 + T cells showed higher expression of CRACR2A transcripts than did murine embryonic fibroblasts (MEFs), whereas CRACR2B transcripts were very low (Fig. 3d) . These data suggest that the relative contribution of CRACR2A and CRACR2B in SOCE in T cells versus HEK293 cells is partially due to differences in their expression levels.
To check for a possible functional redundancy between CRACR2 proteins, we used HEK293 cells stably depleted of CRACR2B by small hairpin (sh)RNA and ectopically expressed CRACR2A or CRACR2B ( Supplementary Information, Fig. S6e ). Expression of CRACR2B completely restored SOCE (Fig. 3e, green trace) , validating the specificity of knockdown. Under these conditions, expression of CRACR2A significantly restored SOCE, indicating a functional redundancy between CRACR2 proteins (Fig. 3e , blue trace). To examine whether both CRACR2 proteins can modulate Orai1 activity, we expressed CRACR2A or CRACR2B in Orai1-null MEFs in the absence or presence of Orai1. Orai1-null MEFs show very low residual SOCE, which is restored to wild-type levels by exogenous expression of Orai1 (Fig. 3f , black and red traces) 34 . Expression of CRACR2A or CRACR2B alone did not restore SOCE in Orai1-null MEFs ( Supplementary Information, Fig. S6f ). However, co-expression of CRACR2A with Orai1 increased the peak [Ca 2+ ] i by more than twofold compared with expression of Orai1 alone (Fig. 3f, bar graph) . In contrast, co-expression of CRACR2B with Orai1 had a very mild effect on SOCE. These data suggest a specific role of CRACR2A in enhancement of Orai1-mediated SOCE that is distinct from CRACR2B. (nM) 0 B r a in H e a r t K id n e y L iv e r L u n g P la c e n t a S k . M u s S p le e n T h y m u s J u r k a t H E K H e L a B r a in H e a r t K id n e y L iv e r L u n g P la c e n t a S k . M u s S p le e n T h y m u s J u r k a t . In contrast, CRACR2A
did not induce large CRAC currents when co-expressed with Orai1 (data not shown), indicating that CRACR2A cannot substitute for STIM1. We hypothesized that binding of CRACR2A to Orai1 and STIM1 may stabilize their interaction in the PM-proximal region, and consequently its (Fig. 4a, bottom) . To investigate the effects of CRACR2A on clustering of Orai1, we transfected control and CRACR2A-depleted Jurkat T cells with plasmids encoding Orai1 fused to an enhanced green fluorescent protein (Orai1-eGFP) and STIM1 fused to the fluorescent protein mCherry (STIM1-mCherry) in an equimolar ratio. Orai1 formed clusters upon thapsigargin treatment in control cells, but CRACR2A depletion impaired this process (Fig. 4b ). These data suggest that CRACR2A is important for clustering of Orai1 and STIM1.
To identify the residues in the Orai1 N terminus necessary for CRACR2A binding, we generated mutants of amino acids conserved in Orai family ( Supplementary Information, Fig. S7a ). In particular, we focused on positively charged residues, because CRACR2A contains many negatively charged residues ( Supplementary Information, Fig. S2 ). GST pulldown assays revealed an important role of positively charged residues in binding to CRACR2A, whereas mutations of conserved serine residues showed impairment (Fig. 4c) . To assess the functional consequence of impaired clustering, we measured SOCE in Orai1-null T cells expressing ] i at 800 s and Ca . Orai1 K85A/K87A could not restore SOCE in Orai1-null CD4 + T cells (Fig. 4d) . Moreover, it had a dominant negative effect on the residual SOCE, suggesting that the residual SOCE may be contributed by other members of the Orai family and hetero-multimerization with Orai1 K85A/ K87A may influence their function. Membrane insertion and expression levels of the Orai1 K85A/K87A mutant were similar to wild type ( Supplementary  Information, Figs S7c and S8 ). To examine whether CRACR2A coexpression can overcome the inability of Orai1 K85A/K87A to rescue SOCE, we generated Orai1-null MEFs stably co-expressing Orai1 K85A/K87A with either CRACR2A or CRACR2B. Indeed, co-expression of CRACR2A with Orai1 K85A/K87A showed significant recovery of SOCE, whereas that of CRACR2B had a marginal effect (Fig. 4e) . These experiments suggest that CRACR2A physically interacts with the positively charged residues in the N terminus of Orai1 and that this interaction is important for clustering and activity of Orai1.
The EF hands of CRACR2A mediate Ca
2+ -sensitive interaction with Orai1 and STIM1
The EF hands are highly conserved among CRACR2 family ( Supplementary Information, Fig. S2 and S5 ). To test whether these predicted EF hands bind Ca 2+ , 45 Ca 2+ overlay analysis was performed using recombinant full-length and various mutants of CRACR2A together with calmodulin (CaM) as a positive control. Wild-type CRACR2A and a mutant lacking the C terminus (∆C) showed binding to Ca 2+ , whereas truncation of the N terminus or mutations in the second EF hand abolished Ca 2+ binding (Fig. 5a ). These results, together with those in Fig. 2 , suggest that the EF-hand motifs of CRACR2A bind to Ca 2+ and that Ca 2+ binding reduces its interaction with Orai1 and STIM1. Our previous data showed that CRACR2A depletion reduced clustering of STIM1 and Orai1 (Fig. 4a, b) . To examine whether co-expression of wild-type or Ca 2+ -insensitive CRACR2A (CRACR2A EF2MUT ) respectively (1), whereas CRACR2A (green) localizes in the cytoplasm. Upon store depletion, Orai1 and STIM1 translocate to form clusters at the junctional regions between PM and ER (2). CRACR2A may be actively involved in translocation of either Orai1 (i) or STIM1 (ii) or both (iii). It is also possible that CRACR2A passively interacts with Orai1 and STIM1 at sites of clustering (iv). On the basis of our data, we propose that CRACR2A is important for stabilization of Orai1-STIM1 complex by direct protein interaction under physiological conditions in which amounts of Orai1 and STIM1 proteins are limiting (3) . Upon increase of cytoplasmic [Ca 2+ ] resulting from opening of CRAC channels, the EF hands of CRACR2A bind Ca 2+ ions, resulting in its dissociation from Orai1 and STIM1 (4), thereby destabilizing the Orai1-STIM1 complex. The EF hands of STIM1 and CRACR2A are indicated and they are shown in red when Ca 2+ is bound. The schematic does not represent the molecular stoichiometry of Orai1, STIM and CRACR2A proteins.
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influences STIM1 clustering, we examined STIM1 localization in HEK293 cells co-expressing CRACR2A
EF2MUT
-mCherry using TIRF microscopy. Cells expressing STIM1-YFP showed minimal clustering under resting conditions (Fig. 5b, top, arrow) . However, in cells coexpressing CRACR2A EF2MUT -mCherry, STIM1 was clustered to varying degrees even without store depletion (see the two separate examples indicated by arrowheads in the top and middle panels of Fig. 5b) . Upon store depletion, clusters of STIM1 expanded to become larger aggregates (Fig. 5b, c) . As mentioned previously ( Supplementary  Information, Fig. S3 ), CRACR2A is a predominantly cytoplasmic protein and was detected everywhere in the footprint of the cell (Fig. 5b) . We could detect preferential accumulation of CRACR2A
EF2MUT at sites of STIM1 clustering upon store depletion (Fig. 5b , middle and bottom panels of TIRF images, arrowheads). Visual examination of cells expressing STIM1 and CRACR2A
EF2MUT revealed that more than 80% of cells had STIM1 in clusters (Fig. 5c) . These results were confirmed independently by using live cell confocal microscopy ( Supplementary  Information, Fig. S9 ). In addition, biochemical analysis also showed STIM1 oligomerization mediated by CRACR2A overexpression. Upon co-expression of CRACR2A, STIM1 and CRACR2A could both be readily detected in high MW complexes without store depletion ( Supplementary Information, Fig. S10a, b (Fig. 6a) . To examine the effect of CRACR2A on endogenous CRAC channel function, we measured SOCE in Jurkat T cells expressing wild-type or mutant CRACR2A. Expression of CRACR2A or CRACR2A EF2MUT enhanced SOCE in Jurkat T cells, with the latter having a stronger effect (Fig. 6b) . We also observed a significant increase in resting [Ca 2+ ] i in Jurkat cells expressing CRACR2A EF2MUT (Fig. 6b , right, and Fig. 6c ), supporting our observations in HEK293 cells.
In T cells, asynchronous [Ca 2+ ] i oscillations evoked by T cell receptor signalling are important for activation of the nuclear factor of activated T cells (NFAT) and nuclear factor (NF)-κB pathways 39, 40 . These oscillations can also be induced by low concentrations of thapsigargin 41 . Consistent with previous observations 41 , control Jurkat T cells showed asynchronous oscillations with an average frequency of 4-6 mHz ( Supplementary  Information, Fig. S11a ) and a marginal increase in average responses from 50 cells (Fig. 6c) . Cells expressing CRACR2A
EF2MUT showed higher basal [Ca 2+ ] i , which increased over time upon treatment with 10 nM thapsigargin (Fig. 6c) . Population average responses were threefold higher in the presence of CRACR2A
EF2MUT when compared with control cells. The oscillations in control cells and cells expressing CRACR2A EF2MUT were blocked by 2-aminoethoxydiphenyl borate (2-APB), implying a role of CRAC channels in these oscillations, as previously reported 41 ( Supplementary Information, Fig. S11b and data not shown) .
Given that overexpression of CRACR2A EF2MUT increased basal [Ca 2+ ] i , we measured its effect on cell death in T cells. Jurkat T cells expressing CRACR2A-GFP or CRACR2A EF2MUT -GFP showed twofold and fivefold increase in apoptotic cell population, respectively, when compared with GFP-expressing cells 72 h after transfection (Fig. 7a, b) . As a result, the population of cells expressing CRACR2A-GFP or CRACR2A EF2MUT -GFP drastically decreased by 72 h, whereas that of control cells remained unchanged (Fig. 7c) . These results suggest that CRACR2A has a pivotal role in regulation of [Ca 2+ ] i and that an uncontrolled increase in [Ca 2+ ] i following expression of CRACR2A
EF2MUT can result in cell death.
DISCUSSION
We have identified CRACR2A as an important component of the Orai1-STIM1 complex. CRACR2A interacts directly with the N terminus of Orai1; however, its co-expression with Orai1 is not sufficient to amplify CRAC currents (data not shown). Instead, CRACR2A seems to act as a stabilizer for the interaction between Orai1 and STIM1. Several lines of experimental evidence support this hypothesis. First, the biochemical analyses showed that CRACR2A interacts directly with both Orai1 and STIM1 and that their interaction increases upon store depletion. Second, depletion of CRACR2A decreases CRAC-channel-mediated SOCE because such depletion reduces clustering of Orai1 and STIM1. Third, CRACR2A facilitates clustering of STIM1 and Orai1 at PM-ER junctions and potentiates SOCE. On the basis of these observations, we propose the following model (Fig. 7d) . Under resting conditions, Orai1 and STIM1 are dispersed in the PM and ER membranes, respectively, and CRACR2A is localized in the cytoplasm (Fig. 7d, 1) . Upon store depletion, STIM1 and Orai1 translocate and cluster at PM-ER junctions. Whether CRACR2A has an active role in translocation of Orai1 and/ or STIM1 (Fig. 7d, 2i -iii) or is recruited into junctions after clustering (Fig. 7d, iv) awaits further studies. Given that Orai1 translocation depends on STIM1, CRACR2A is likely to be involved in translocation of STIM1 or of both Orai1 and STIM1 (Fig. 7d, 2ii and iii) rather than Orai1 alone (Fig. 7d, 2i) . In all the scenarios, our results suggest the presence of a ternary complex of Orai1, STIM1 and CRACR2A (Fig. 7d, 3 ) that dissociates when [Ca 2+ ] i is elevated (Fig. 7d, 4 ). CRACR2A may have an important role in a physiological context in which the amount of Orai1 and STIM1 is limiting, unlike when there is transient overexpression of Orai1 and STIM1. Recently, CaM binding to the N terminus of Orai1 has been shown to evoke inactivation of CRAC channels 42 . CaM binding sites on Orai1 and STIM1 partially overlap with those of CRACR2A 42, 43 . In addition, CRACR2A and CaM have comparable affinity for Ca 2+ (Fig. 5a) 
METhODS
Reagents and antibodies. Fura 2-AM, Fura 4F-AM and Lipofectamine 2000 were obtained from Invitrogen. Anti-FLAG antibody (F3165) from Sigma-Aldrich was used at 1:10,000 dilution. STIM1 was detected using monoclonal antibody (No. 610954, BD Biosciences) at 1:2,000 dilution. Anti-actin (sc-1616) and anti-Myc (sc-47694) antibodies were purchased from Santa Cruz Biotechnologies (1:2,000 dilution). Polyclonal rabbit antibody for detection of CRACR2A was generated using purified human CRACR2A protein (Open Biosystems) and used at 1:10,000 dilution.
Plasmids and cells.
Full-length cDNAs of human Orai family and STIM1 were subcloned into pMSCV-CITE-eGFP-PGK-Puro 16 . For generation of STIM1-YFP and STIM1-mCherry, cDNA was cloned into pEYFP-N1 or pmCherry-N1 plasmids (Clontech). The Orai1 K85A/K87A mutant was generated with an extracellular FLAG tag in the pMSCV-CITE-eGFP-PGK-Puro vector and with C-terminal GFP in the pEGFP-N1 vector. Full-length cDNAs for human CRACR2A (clone ID 3531511) and mouse CRACR2B (clone ID 5256663) were purchased from Open Biosystems and subcloned into the pMSCV-CITE-eGFP-PGK-Puro vector with a FLAG tag. A plasmid encoding Myc-CRACR2A was generated by subcloning into pcDNA3.1mychis (Invitrogen). Wild-type CRACR2A or CRACR2A EF2MUT cDNA was subcloned into the pEGFP-N1, pEGFP-C1 and pmCherry-N1 plasmids. CRACR2B cDNA was subcloned into the pcDNA3.1mychis and pMSCV-CITE-eGFP-PGK-Puro vectors. Primers used are described in Supplementary Information, Table S1 . HEK293, HeLa and Jurkat T cell lines were obtained from the American Type Culture Collection (ATCC). HeLa O+S cells were generated by transducing with viruses encoding FLAG-tagged Orai1 and untagged STIM1 (1:3 ratio) together with hCD25 (refs 44, 45) followed by selection using hCD25 antibody-coated magnetic beads (Invitrogen).
Glycerol gradient analysis, affinity protein purification and mass spectrometry. HeLa O+S cells (2 x 10
10
) were left untreated or treated with 1 µM thapsigargin for 10 min in PBS buffer and cross-linked with 0.5 mM dithiobis succinimidyl propionate (DSP) for 1 h on ice, followed by quenching with 20 mM Tris-Cl, pH 7.5. Cells were lysed in cell lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 100 mM NaCl, 10% glycerol, 0.5% Igepal CA-630 and Roche protease inhibitor cocktail). Precleared lysates were applied onto a 20-50% glycerol cushion and centrifuged at 288,000g for 16 h. Fifty-six fractions were collected from the top and analysed by immunoblotting. Orai1-containing fractions were pooled and immunoprecipitated overnight at 4 °C with anti-FLAG antibody agarose, washed five times in lysis buffer with high salt (200 mM NaCl) and five times with low salt buffer (100 mM NaCl), and eluted with the FLAG peptide (0.1 mg/ml). The eluates were run on an SDS-PAGE gel and analysed by silver staining or Colloidal Blue Staining Kit (Invitrogen) for mass spectrometry. In-gel digestion with trypsin, nano liquid chromatography tandem mass spectrometry (nanoLC-MS/MS) and automated database searching were performed essentially as described previously 46 .
Immunoprecipitation and GST pulldown analysis. Transfected HEK293 or HeLa cells (2 x 10 7 ) were harvested in PBS and DSP cross-linked. Cells were lysed in lysis buffer (20 mM Tris-Cl, 2 mM EDTA, 100 mM NaCl, 10% glycerol, 0.5% Igepal CA-630, Roche protease inhibitor cocktail) and centrifuged at 100,000g for 1 h before preclearing with protein-G-Sepharose. Lysates were immunoprecipitated overnight with anti-FLAG antibody agarose. Immunoprecipitates were washed in lysis buffer and analysed by immunoblotting. For pulldown analysis, the GST-fused N terminus of Orai1, STIM1 fragments and 6X His-tagged fulllength CRACR2A were incubated with glutathione Sepharose 4B beads for 6 h in binding buffer (0.1% Igepal CA-630, 20 mM Tris-HCl, 100 mM NaCl, 2 mM EDTA, protease inhibitors, 10% glycerol and 100 µg/ml bovine serum albumin) with or without 2 mM CaCl 2 . After extensive washing, proteins bound to beads were analysed by immunoblotting.
Purification of recombinant proteins from insect cells and E. coli.
Full-length FLAG-tagged human Orai1 and STIM1 cDNAs were integrated into baculoviruses, expressed in Sf9 cells and purified following manufacturer's instructions (Bac-to-Bac Baculovirus Expression Systems, Invitrogen). Orai1, STIM1 fragments and full-length CRACR2A proteins were subcloned into pGEX4T-1 and pET21A plasmids. Transformants expressing GST fusion protein were grown in liquid cultures and induced with isopropyl-1-thio-β-d-galactopyranoside (IPTG, 0.2 mM) at 18 °C overnight. Subsequently, cells were harvested and resuspended in lysis buffer (50 mM NaH 2 PO 4 , 500 mM NaCl, 10% glycerol, pH 8.0) containing protease inhibitors and 0.5% Triton X-100. The lysates were incubated with glutathione Sepharose 4B beads for 2 h. The recombinant proteins were eluted using glutathione. For 6X His-tagged proteins, cells were harvested and resuspended in lysis buffer (50 mM NaH 2 PO 4 , 500 mM NaCl, 10% glycerol, 0.5% Triton X-100 and 10 mM imidazole, pH 8.0). After sonication and clearing, the supernatant was incubated with Ni-NTA agarose (Qiagen). The recombinant proteins were eluted in buffer containing 250 mM imidazole.
siRNA/shRNA-mediated depletion and quantitative PCR. HEK293 cells (0.5 x 10 6 ) were transfected with siRNAs (Dharmacon) using lipofectamine reagent. Cells were re-transfected after 24 h and harvested for RT-PCR or [Ca 2+ ] i measurement 3 days after transfection. Jurkat cells were electroporated with 100 nM of siRNA and used for experiments 3 days after transfection. The sequences of siRNAs are: hOrai1, 5´-UCACUGGUUAGCCAUAAGA-3´; hCRACR2A, 5´-GCUCAGCAGCAGUUGGAAA-3´; hCRACR2B, 5´-GAACA-UGCAGAAAGAGAAA-3´. Knockdown efficiency was quantified by RT-PCR analysis. Purified RNA was oligo(dT)-primed for first-strand cDNA synthesis (Superscript III kit, Invitrogen). Quantitative real-time PCR using the dye SYBR green was performed using an iCycler IQ5 (Bio-Rad). The cDNA levels were normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Sequences of the primers are mentioned in Supplementary Information, Table S1 . For shRNA expression, the corresponding sense and antisense siRNA sequences were subcloned into pRetro-Super-puro (OligoEngine). For assessment of expression of CRACR2A and CRACR2B in various human tissues, cDNA made from commercially available purified total RNA (Applied Biosystems, Foster City, CA) was used for PCR with primers ( Supplementary Information, Table S1 ).
Single-cell Ca
2+ imaging, TIRF and confocal microscopy. T cells were loaded at 1 x 10 6 cells per ml with 1 µM Fura 2-AM for 30 min at 25 °C and attached to poly-l-lysine-coated coverslips. Fibroblasts, HeLa cells and HEK293 cells were grown directly on UV-sterilized coverslips and loaded with 2 µM Fura 2-AM for 45 min. For SOCE measurements in Fig. 6a and 6b, cells were loaded with 2 µM Fura 4F-AM for 45 min. Intracellular [Ca 2+ ] i measurements were performed using essentially the same methods as previously described 47 . TIRF microscopy was performed using an Olympus IX2 illumination system mounted on an Olympus IX51 inverted microscope using previously described methods 47 . For quantification of TIRF intensity across different cells, individual regions of interest were selected and data were analysed as the ratio of fluorescence intensity at each time-point (F) to the fluorescence intensity at the start of the experiment (F 0 ). For confocal analysis, at 6 h after transfection, HEK293 cells were plated onto sterilized coverslips and maintained in complete DMEM medium for 18 h before imaging in Ringer's solution containing: 155mM NaCl, 4.5mM KCl, 2mM CaCl 2 , 1mM MgCl 2 , 10mM d-glucose, and 5mM Na-HEPES (pH 7.4). For depletion of stores, cells were treated with 1 µM thapsigargin in Ca 2+ -free Ringer's solution (prepared by substitution of CaCl 2 with 2 mM MgCl 2 and 0.2 mM EGTA) for 5 min. eGFP and mCherry were excited simultaneously at 488 and 594 nm on a Leica SP2 AOBS inverted confocal microscope equipped with a PL APO 60x/NA 1.4 oil immersion objective. Fluorescence emission was collected at 615-700 nm (mCherry) and 510-570 nm (eGFP). Images were processed for enhancement of brightness or contrast using LCSlite (Leica) software.
T cell purification, cytokine measurement, Annexin V staining and immunocytochemistry. T cell purification, activation and transduction were carried out as previously described 47 . Cells were harvested and used for measurement of Ca 2+ entry or RNA extraction after 5-6 days of stimulation. Jurkat T cells were electroporated with 20 µg of plasmids. For intracellular cytokine staining, Jurkat T cells were stimulated with 10 nM phorbol 12-myristate 13-acetate (PMA) and 1 µM ionomycin for 16 h. Cells were fixed with 4% paraformaldehyde in PBS and permeabilized in saponin buffer (PBS, 0.5% saponin, 1% bovine serum albumin and 0.1% sodium azide). Cells were stained with phycoerythrin-conjugated human IL-2 antibody (eBioscience) for 20 min, washed and analysed. For the apoptosis assay, transfected Jurkat T cells were stained using Annexin V staining kit (BD Biosciences). Cells were examined on a FACSCalibur flow cytometer (BD Biosciences). Immunocytochemistry and flow cytometry on HEK293 cells expressing wild-type and mutant Orai1 constructs were performed as described 47 .
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Measurement of CRAC currents by whole cell patch clamp recording. CRAC current measurements were carried out as previously described 47 .
Fluorescence protease protection assays. FPP assays were performed using a previously described protocol 33 . Briefly, HEK293 cells expressing GFP-CRACR2A or CRACR2A-GFP on UV-sterilized coverslips were perfused with KHM buffer (110 mM potassium acetate, 20 mM HEPES and 2 mM MgCl 2 ). For permeabilization, 75 µM digitonin was used. Subsequently 50 µg ml -1 proteinase K containing KHM buffer was perfused. GFP images were acquired at every 5-s interval after background subtraction. For each experiment, 50-100 individual HEK293 cells were analysed using OriginPro (Originlab).
Detection of Ca
2+ binding using the 45 Ca 2+ overlay method. 45 CaCl 2 (1 mCi, 37 MBq) was purchased from NEN. The protocol was modified from a previously described method 48 . Purified 6X His-fusion proteins and CaM (EMD Biosciences) were transferred to a nylon membrane after separating on a 12% SDS-PAGE. The blot was extensively washed for 3 x 30 min with binding buffer (in mM: 60 KCl, 5 MgCl 2 , and 10 imidazole-HCl, pH 6.8).
The overlay assay was performed by incubating the blot with 8.8 µM 45 CaCl 2 at 25 °C for 1 h, followed by 3 x 5 min washes in distilled H 2 O. After autoradiography, the blot was stained with Ponceau S solution for detection of proteins.
Statistical analysis. Statistical analysis was carried out using Student's t-test. Amino acid sequences of human, chimpanzee, mouse and zebrafish CRACR2A proteins were aligned using ClustalW2 (default options). The predicated conserved EF-hands are colored in light blue (predicted using SMART). The predicted coiled-coil sequence (Human Protein Reference Database and COILS) in the C terminus is boxed in gray and tropomyosin domains predicted using PRINTS are highlighted in blue. The CRACR2A peptide detected from mass spectrometry is shown in red. This peptide was detected in a gel fragment corresponding to MW of ~45 kDa as described in Fig. 1 . In humans, three alternative transcripts of CRACR2A (NM_001144958.1, NM_001144959.1 and NM_032680.3) were identified. Proteins derived from three isoforms are identical in their first 372 amino acids with differences in their C-terminal sequences. Amino acids sequences corresponding to isoform c of CRACR2A (predicted MW; 45.6 kDa, Compute pI/Mw tool) have been aligned here. 
Tropomyosin domain
Zebra fish RETSVENVKLKRYNEDLSRELDHTSQELSLAQEQLMLLQEQSSRLHEEREM---------334
shown in red. This peptide was detected in a gel f t di t MW f 45 kD CRACR2A from various species. Amino acid sequences of human, chimpanzee, mouse and zebrafish CRACR2A proteins were aligned using ClustalW2 (default options). The predicated conserved EF-hands are colored in light blue (predicted using SMART). The predicted coiledcoil sequence (Human Protein Reference Database and COILS) in the C terminus is boxed in gray and tropomyosin domains predicted using fragment corresponding to MW of ~45 kDa as described in Fig. 1 . In humans, three alternative transcripts of CRACR2A (NM_001144958.1, NM_001144959.1 and NM_032680.3) were identified. Proteins derived from three isoforms are identical in their first 372 amino acids with differences in their C-terminal sequences. Amino acids sequences corresponding to isoform c of CRACR2A (predicted MW; 45 6 kDa Compute in gray and tropomyosin domains predicted using PRINTS are highlighted in blue. The CRACR2A peptide detected from mass spectrometry is CRACR2A (predicted MW; 45.6 kDa, Compute pI/Mw tool) have been aligned here. -N) , the intracellular loop (Orai1-IC) or the C-terminus (Orai1-C) of Orai1 were separated by SDS-PAGE (labeled as induced) together with purified fragments (labeled as purified) and visualized by coomassie blue staining (left). Lysates of E.coli expressing 6X His-tagged truncation or point mutants of CRACR2A proteins were analyzed by SDS-PAGE and coomassie blue staining (right). Uninduced, induced cell lysates and proteins purified using Ni 2+ resins were examined. M, molecular weight marker. MASPGLPGSGEGQEGE-ETTGVSARHGVEVLQQAQELFLLCDKDAKGFITRQDLQGLQSD 59 ***** **:.*.** * * * ** . :*:**:********:******::******** hCRACR2B LPLTPEQLEAVFESLDRAHTGFLTAREFCLGLGMFVGVASAQGANPCRTPEETFESGGLD 120 mCRACR2B LPLTPEQLEAVFESLDQAHTGFLTAREFCLGLGKFVGVESAPGGSPLRTSEETFESG---116 ****************:**************** **** ** *..* **.******* ---TGGSLEEEEEDVETFYTSLEKLGVARVLGEQWAVRTLWVGLQRERPELLGSLEEVLM 173 *.***:****: * *:* **:**** ***:* ******. ***********:*:**: hCRACR2B RASACLEEAARERDGLEQALRRRESEHEREVRALYEETEQ-LREQSRRPPSQNFARGERR 239 mCRACR2B RASACLEAAAREREGLEQALRRRESEHEREVRGLYEELEQQLGEQRHRRQSQNLPREEQR 233 ******* *****:******************.**** ** * ** :* ***:.* *:* hCRACR2B SRLELELQSREQDLERAGLRQRELEQQLHAQAAEHLEAQAQNSQLWRAHEALRTQLEGAQ 299 mCRACR2B GHLELELQTREQELERAGLRQRELEQQLQARAAEQLEAQAQHIQLQRAYEAIRAQLDQAQ 293
Coiled-coil
:******:***:***************:*:***:******: ** **:**:*:**: ** hCRACR2B EQIRRLESEARGRQEQTQRDVVAVSRNMQKEKVSLLRQLELLRELNTRLRDDRDACEARR 359 mCRACR2B EQLSRLEGEAQGRQEQTQRDVVAVSRNMQKEKLSLLRQLELLRELNLRLRDERDACETKL 353 **: ***.**:*********************:************* ****:*****::
LGSSHRKALAIAHKPGPIYCCCCCGWARPPRRGSGHLPSAR 394 *** ****: *: *** ***** **************** is the residue mutated to Trp (R91W) in human SCID patients (green). The first transmembrane segment (TM I) and the pore residue, E106 are indicated in blue and asterisk (*), respectively. (b) GST pulldown assays with wildtype and mutant Orai1 N terminus fragments. In addition to the positively charged residues, the conserved serine residues were examined for their role in CRACR2A binding (left). Pulldown with the N terminus of Orai1 K85A/K87A double mutant shows minimal binding to CRACR2A (right). Lower panels show the amount of GST fusion proteins using immunoblots. All the GST-fused WT, mutant Orai1 fragments, and full-length CRACR2A proteins were purified from E. coli. Full scans of blots are shown in Supplementary Information, Fig.  S12 . (c) HeLa cells stably expressing STIM1 were transfected with plasmids encoding Myc-CRACR2A together with either WT Orai1 or Orai1 K85/K87A mutant. After 48 h, cells were treated with 1 µM thapsigargin, cross-linked with DSP and examined by immunoblotting for expression of WT Orai1, Orai1 K85/K87A and CRACR2A (Input). Middle panel shows input levels using immunoblot with anti-actin antibody. After immunoprecipitation with anti-FLAG resin, precipitates were analyzed by immunoblotting with anti-FLAG and anti-Myc antibodies for detection of Orai1 and CRACR2A, respectively (IP). As a control for surface staining, HEK293 cells were transfected with a plasmid encoding C-terminally FLAG-tagged Orai1 (WT-C-FLAG). Bar, 10 mm. (b) HEK293 cells expressing either WT or Orai1 K85A/87A mutant were permeabilized, stained for Orai1, and examined using flow cytometry. Since this plasmid also expressed GFP from IRES site, only GFP + population was gated for analysis. At least 30,000 events were collected for each sample. cells were transfected with a plasmid encoding C terminally FLAG-tagged Orai1 (WT-C-FLAG). Bar, 10 m. (b) HEK293 cells expressing either WT or Orai1 K85A/87A mutant were permeabilized, stained for Orai1, and examined using flow cytometry. Since this plasmid also expressed GFP from IRES site, only GFP + population was gated for analysis. At least 30,000 events were collected for each sample. 
